Carvedilol
Product Images NDC 70518-3640

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 70518-3640). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Carvedilol 3.125mg 70518 3640 01)

Carvedilol is a medication for which one tablet of 3.125 mg is available in the pack. The manufacturer of the medication is Aurohindo in Nagar, India. The medication should be kept out of the reach of children and stored at a temperature between 15-30°C (59-86°F). There are directions specified in the package insert for its usage. The medication was repackaged by RemedyRepack Inc. in Indiana, PA. The lot number, and expiration date are not available from the given text.*

FDA Label Image

Remedy_label (Remedy Label)

Carvedilol is a tablet medication with a strength of 3.125 mg, packaged in a box of 100 tablets by Aurohindo in Nagar, India. The medication is only available by prescription and should be kept out of reach of children. Instructions for use can be found in the package insert, and the medication should be stored at temperatures between 20-25°C (88-77°F), with temperature excursions permitted up to 15-30°C (59-86°F). This particular box of medication has been repackaged by RemedyRepack Inc. in Indiana, PA 15701. The expiration date and LOT number are not available from the provided information.*

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)

This is a figure or graph showing the effects on mortality for different subgroups in COPERNICUS. The subgroups are categorized by gender, age, race, diabetic or non-diabetic, ischemic or non-ischemic, heart rate, blood pressure, and whether or not they were taking spironolactone. The hazard ratio is also shown. The figure shows the results for each subgroup at different time intervals.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)

FDA Label Image

Chemical Structure (Carvedilol Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.